Company News

BASF Invests in 3Helix To Commercialize Collagen-Hybridizing Peptides for Personal Care

Equity investment and licensing agreement for the biotech start-up’s proprietary CHP technology.

Author Image

By: Christine Esposito

Editor-in-Chief

BASF and 3Helix Inc., a US-based technology start-up, have formed a partnership on 3Helix’s proprietary CHP technology. The partnership involves an equity investment and licensing agreement, granting BASF exclusive rights to commercialize CHP solutions for the personal care field. 3Helix's patented CHP technology is based on short, single-stranded collagen-like peptides that have the unique ability to bind to damaged and denatured collagen, enabling extraordinary anti-aging claims. Th...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters